TransplantRECOVERYNCT05717842
Simultaneous Prospective Kidney Transplant Assessment in Combined Liver Kidney Candidates
An observational study of Transplant, run by Indiana University at 1 site in United States.
Trial summary
The purpose of the study is to determine how much a persons kidney function recovers after receiving a simultaneous liver kidney transplant. The investigators will be contacting patients with kidney dysfunction with estimated GFR between 25 and 40 (not on dialysis treatment) who are listed to receive a simultaneous… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Transplant
- What is being tested?
- Nuclear Medicine Scan
- Type of treatment
- Surgery or procedure
- How many people
- 15 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Dec 2023to Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Individuals who have end stage liver disease (ESLD) and kidney dysfunction, who are not on dialysis and have eGFR >=25 and <=40 ml/min for a duration of at least 6 weeks.
Who may be able to join
- > 18 years old
- Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis at time of transplant surgery)
- Candidates with two native kidneys.
- Willing to participate and sign informed consent form.
Who cannot join
- Unstable patients (e.g. in the ICU or those who are on Continuous Renal Replacement Therapy (CRRT) who cannot complete the nuclear medicine scan or those with AKI on Hemodialysis
- Prior history of any solid organ transplant.
- Those who are currently pregnant or breast feeding.
- Patients who have Autosomal Dominant polycystic kidney disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
IU Health University Hospital
Indianapolis, Indiana, 46202
Muhammad Y Jan
About this study
Official title: Simultaneous Prospective Kidney Transplant Assessment in Combined Liver Kidney
The purpose of the study is to determine how much a persons kidney function recovers after receiving a simultaneous liver kidney transplant. The investigators will be contacting patients with kidney dysfunction with estimated GFR between 25 and 40 (not on dialysis treatment) who are listed to receive a simultaneous liver kidney (SLK) transplant to look at this function recovery. The investigators hope to develop a criteria based on GFR measurement, kidney function calculations from native kidneys vs transplanted kidney and compare the contributions, and correlate with estimated GFR on basic metabolic panel (BMP: a blood test) to predict higher chances of recovery of native kidney function.
Read the detailed description
Study design
Study will be a pilot longitudinal prospective study. SLK transplant listed patients will be recruited from the outpatient Liver Kidney Transplant Clinic at Medical Diagnostic Clinic (MDC) as well as inpatients admitted to IU University Hospital. Listing status for SLK transplant will be confirmed and patients will be scheduled for a Mag3 nuclear medicine scan at IU University Department of Nuclear medicine. For study purposes, this scan will be done pre and post-transplant to compare the results.
Methods:
Inclusion/Exclusion criteria:
Inclusion:
- > 18 years old
- Listed for Liver Transplant for ESLD and Kidney Transplant based on eGFR ranging from ≥ 25 to ≤40 mL/min/1.73m2 (not on dialysis at time of surgery)
- Candidates with two native kidneys.
- Willing to participate and sign informed consent form.
Exclusion Criteria:
- Unstable patients (e.g. in the ICU or those who are on Continous Renal Replacement Therapy (CRRT) who cannot complete the nuclear medicine scan or those on Hemodialysis
- Prior history of any solid organ transplant.
- Those who are currently pregnant or breast feeding.
- Patients with a history of Adult Polycystic Kidney Disease
Data collection: Data collection will be done in RedCap©️ These data forms will incorporate a comprehensive list of variables:
- Participants demographics and BMI
- Reason for ESLD and complications listed in Medical Chart
- Medication list
- Results of Nuclear medicine scan, eGFR on Basic Metabolic Panel, measurement of eGFR by Cystatin C, 24 hour urinary creatinine clearance and measurement of urinary NGAL level. Radiographically: kidney size, presence of findings such as cysts, stones etc.
- Post SLK transplant complications including need for Dialysis, delayed graft function, episodes of rejection, infections and any reason for admission to the hospital
- Adherent to Immunosuppression regimen, and type of Immunosuppression regimen
- BP readings at follow up clinic visits
- Any post SLK transplant imaging for kidney size and any findings (if any imaging is performed for any other indication, none will done for the research study).
Participants will be informed about the results of their studies. Participation will be voluntary. Compensation will be provided once in the form of $25 gift card that will be provided upon completing participation for the nuclear medicine scan 10 months after patients receive their SLK transplant. Patients and their insurance will not be charged and the testing will be invoiced to the study grant.
Provisions for post-study care No provision will be provided for care regarding incidental findings on the nuclear medicine scan. They will be given information regarding referral to seeking appropriate care. No expenses will be reimbursed for this care.
Participant timeline:
Enrollment of participants will be done starting February 2023 and completed by December 2023
Statistical Analyses:
Sample size:
Estimated number of participants is determined by participants listed for SLK transplant. An estimated 15 participants are planned to be recruited. As this is a pilot study, all participants at IU will be asked to participate with a future goal of a multi-center study.
Plans for assessment and collection of outcomes:
Data will be collected in IU RedCap registry, which is a secure platform. Data will be entered in Redcap, coded, secured, and stored. Any raw data collection (source documents) will be kept in a locked cabinet in a locked office. Data will be processed with SPSS data management software.
Confidentiality Information about potential and enrolled participants will be collected, shared, and maintained in a manner that protects confidentiality before, during, and after the study.
- Conditions
- Transplant
- Being tested
- Nuclear Medicine Scan
- Keywords
- Liver, Kidney
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nuclear Medicine ScanRadiation
Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
| Study group | Role | What they receive |
|---|---|---|
| People with ESLD and eGFR between >=25 and <=40ml/min | 1. > 18 years old
2. Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis)
3. Candidates with two native kidneys.
4. Willing to participate and sign informed consent Receives: Radiation: Nuclear Medicine Scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
perform a nuclear medicine scan prior to SLK transplant
To determine split kidney function with a Mag3 (Mercaptoacetyltriglycine 3) nuclear medicine renal scan as part of the study procedures.
Measured: up to 100 weeks
Secondary outcomes (1)
To measure and correlate Clinical, laboratory and Radiographic data at the time of SLK transplant will be reviewed
This includes standard testing performed at our center prior to SLK transplant which are standard of care. This will include measurement of eGFR by Cystatin C.
Measured: up to 100 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Feb 2023
- Study start8 Dec 2023
- Primary completionDec 2026 (estimated)
- Study completionFeb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TransplantStudies of the same condition, open and under way.
- More trials run by Indiana UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Collaborators
- Jerome A. Josephs Fund for Transplant Innovation Fund
- Responsible party
- Principal investigator, Muhammad Yahya Jan, Indiana University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05717842
- Sponsor's protocol ID
- 15853
- Acronym
- RECOVERY
- Status last verified
- Mar 2026
- First submitted
- 2 Dec 2022
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Simultaneous Prospective Kidney Transplant Assessment in Combined Liver Kidney
- ClinicalTrials.gov ID
- NCT05717842
- Acronym / sponsor ID
- RECOVERY / 15853
- Conditions
- Transplant
- Keywords
- Liver, Kidney
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Indiana UniversityUniversity, hospital or other
- Collaborators
- Jerome A. Josephs Fund for Transplant Innovation Fund
- Study start
- 8 Dec 2023 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Feb 2027 (estimated)
- First posted
- 8 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to determine how much a persons kidney function recovers after receiving a simultaneous liver kidney transplant. The investigators will be contacting patients with kidney dysfunction with estimated GFR between 25 and 40 (not on dialysis treatment) who are listed to receive a simultaneous liver kidney (SLK) transplant to look at this function recovery. The investigators hope to develop a criteria based on GFR measurement, kidney function calculations from native kidneys vs transplanted kidney and compare the contributions, and correlate with estimated GFR on basic metabolic panel (BMP: a blood test) to predict higher chances of recovery of native kidney function.
Detailed description
Study design
Study will be a pilot longitudinal prospective study. SLK transplant listed patients will be recruited from the outpatient Liver Kidney Transplant Clinic at Medical Diagnostic Clinic (MDC) as well as inpatients admitted to IU University Hospital. Listing status for SLK transplant will be confirmed and patients will be scheduled for a Mag3 nuclear medicine scan at IU University Department of Nuclear medicine. For study purposes, this scan will be done pre and post-transplant to compare the results.
Methods:
Inclusion/Exclusion criteria:
Inclusion:
- > 18 years old
- Listed for Liver Transplant for ESLD and Kidney Transplant based on eGFR ranging from ≥ 25 to ≤40 mL/min/1.73m2 (not on dialysis at time of surgery)
- Candidates with two native kidneys.
- Willing to participate and sign informed consent form.
Exclusion Criteria:
- Unstable patients (e.g. in the ICU or those who are on Continous Renal Replacement Therapy (CRRT) who cannot complete the nuclear medicine scan or those on Hemodialysis
- Prior history of any solid organ transplant.
- Those who are currently pregnant or breast feeding.
- Patients with a history of Adult Polycystic Kidney Disease
Data collection: Data collection will be done in RedCap©️ These data forms will incorporate a comprehensive list of variables:
- Participants demographics and BMI
- Reason for ESLD and complications listed in Medical Chart
- Medication list
- Results of Nuclear medicine scan, eGFR on Basic Metabolic Panel, measurement of eGFR by Cystatin C, 24 hour urinary creatinine clearance and measurement of urinary NGAL level. Radiographically: kidney size, presence of findings such as cysts, stones etc.
- Post SLK transplant complications including need for Dialysis, delayed graft function, episodes of rejection, infections and any reason for admission to the hospital
- Adherent to Immunosuppression regimen, and type of Immunosuppression regimen
- BP readings at follow up clinic visits
- Any post SLK transplant imaging for kidney size and any findings (if any imaging is performed for any other indication, none will done for the research study).
Participants will be informed about the results of their studies. Participation will be voluntary. Compensation will be provided once in the form of $25 gift card that will be provided upon completing participation for the nuclear medicine scan 10 months after patients receive their SLK transplant. Patients and their insurance will not be charged and the testing will be invoiced to the study grant.
Provisions for post-study care No provision will be provided for care regarding incidental findings on the nuclear medicine scan. They will be given information regarding referral to seeking appropriate care. No expenses will be reimbursed for this care.
Participant timeline:
Enrollment of participants will be done starting February 2023 and completed by December 2023
Statistical Analyses:
Sample size:
Estimated number of participants is determined by participants listed for SLK transplant. An estimated 15 participants are planned to be recruited. As this is a pilot study, all participants at IU will be asked to participate with a future goal of a multi-center study.
Plans for assessment and collection of outcomes:
Data will be collected in IU RedCap registry, which is a secure platform. Data will be entered in Redcap, coded, secured, and stored. Any raw data collection (source documents) will be kept in a locked cabinet in a locked office. Data will be processed with SPSS data management software.
Confidentiality Information about potential and enrolled participants will be collected, shared, and maintained in a manner that protects confidentiality before, during, and after the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| People with ESLD and eGFR between >=25 and <=40ml/min | – | Radiation: Nuclear Medicine Scan1. > 18 years old 2. Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis) 3. Candidates with two native kidneys. 4. Willing to participate and sign informed consent |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals who have end stage liver disease (ESLD) and kidney dysfunction, who are not on dialysis and have eGFR >=25 and <=40 ml/min for a duration of at least 6 weeks.
Key inclusion criteria (4 listed)
- > 18 years old
- Listed for Liver Transplant for ESLD and Kidney Transplant (not on dialysis at time of transplant surgery)
- Candidates with two native kidneys.
- Willing to participate and sign informed consent form.
Key exclusion criteria (4 listed)
- Unstable patients (e.g. in the ICU or those who are on Continuous Renal Replacement Therapy (CRRT) who cannot complete the nuclear medicine scan or those with AKI on Hemodialysis
- Prior history of any solid organ transplant.
- Those who are currently pregnant or breast feeding.
- Patients who have Autosomal Dominant polycystic kidney disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nuclear Medicine ScanMercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan | Radiation | People with ESLD and eGFR between >=25 and <=40ml/min |
Primary outcome
perform a nuclear medicine scan prior to SLK transplant
Time frame: up to 100 weeks
To determine split kidney function with a Mag3 (Mercaptoacetyltriglycine 3) nuclear medicine renal scan as part of the study procedures.
1 secondary outcome
To measure and correlate Clinical, laboratory and Radiographic data at the time of SLK transplant will be reviewed
Time frame: up to 100 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Transplant
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingPhase 2
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-Mediated Rejection (AMR)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Transplant, run by Indiana University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mary Balmes-Fenwick, B.S. (317-948-7772, mbalmes@iu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
perform a nuclear medicine scan prior to SLK transplant (time frame: up to 100 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.